#tumoredelpolmone, una nuova combinazione terapeutica mostra risultati nei pazienti con mutazione EGFR e alterazione del gene MET, precedentemente trattati con osimertinib. Lo studio presentato ad #ESMO26: https://www.medinews.it/comunicati/osimertinib-in-associazione-a-savolitinib-ha-ridotto-il-rischio-di-progressione-del-45-nel-tumore-del-polmone-con-mutazione-egfr-e-alterazione-del-gene-met-in-seguito-a-progressione-da-osimertinib/
@myESMO
6 浏览 · 0 赞 · 0 转发 · 0 回复
Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgOsimertinib (osi) rechallenge after interstitial lung disease (ILD) during osi treatment (tx) in EGFR-mutated advanced non-small cell lung cancer (NSCLC): A retrospective chart review study
https://esmocongress.esmo.orgFLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgPACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.org来源：Ritrattodellasalute · x.com